UNSPSC 51391803: Mephentermine

This classification denotes a cns stimulant with the molecular formula C11H17N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier TEZ91L71V4, chemically known as phenethylamine, n,alpha,alpha-trimethyl- but generally known as mephentermine, which bears US NIH Compound Identifier 3677. European Medicines Agency schedules Mephentermine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08748MIG.

UNSPSC 51391803 Mephentermine is a Commodity code that encompasses pharmaceutical products and related medical supplies, though recent state and local activity under this code shows limited direct alignment with the code's nominal scope. The two most recent opportunities tagged to this code — one for naloxone and drug deactivation systems from Seminole County, Florida, and one for a therapeutic pharmacy initiative from Texas HHS — both address pharmacy procurement and pharmaceutical supply chain management, but neither involves mephentermine directly. State and local governments using codes in this family are primarily health departments, county health systems, and state health agencies acquiring pharmaceutical products to support public health and emergency response initiatives.

Activity under this code spans at least Florida and Texas, with the Seminole County IFB (IFB60459723LAS) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, due July 26, 2023, and the Texas Health and Human Services Commission issuing an RFI (HHS0017013) on April 3, 2026, to explore direct-to-manufacturer prescription programs and vendor capabilities for implementing value-based pharmacy benefit contracting. The Seminole County procurement requires E-Verify compliance, drug-free workplace certification, and standard insurance coverage, with a two-year initial term plus one-year renewal option. The Texas RFI functions as preliminary market intelligence rather than a binding solicitation and does not specify budget or formal evaluation criteria at this stage. Code activity appears sporadic and geographically dispersed; no single issuing body shows repeat solicitation patterns in the available record, and mephentermine-specific procurement is not evident in recent opportunities.